

102nd WPI-IIIS Seminar

Improved therapies by tissue targeting: liver targeted prolyl hydroxylase inhibitors as a novel approach for the treatment of anemia

The discovery of therapies with enhanced safety and efficacy remains a key challenge for the pharmaceutical industry. Liver targeting has emerged as one potential approach toward this end. This presentation will describe the principles that allow for targeting therapeutics to the liver while minimizing systemic exposure. We will show how this strategy can be applied to the discovery of novel liver targeted inhibitors of the hypoxia inducible factor prolyl hydroxylase (HIF-PHD) enzymes as a potential treatment for anemia.



Dr. Christopher Sinz

Merck Research Laboratories,
Merck & Co., Inc.

Date: **Wednesday, January 25, 2017**

Time: **12:00 – 13:00**

Venue: **1F Auditorium, IIIS Building**



IIIS

INTERNATIONAL INSTITUTE FOR INTEGRATIVE
SLEEP MEDICINE



Contact: International Institute for Integrative Sleep Medicine, University of Tsukuba
029-853-8080 (ext. 8080) | wpi-iiis-alliance@ml.cc.tsukuba.ac.jp